Meningococcal Disease
📧 Sign up to get email alerts when something new happens for Meningococcal Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-12-03Clinical Trial Update: Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea [Phase 3]
Phase 3 safety and immunogenicity trial comparing Menactra to Adacel in individuals aged 11 to 55 in South Korea has completed, with results…
-
CLINICAL_TRIALS trial_result · 2013-11-20Clinical Trial Update: Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents [Phase 2]
Phase 2 clinical trial evaluating the safety and immune response of a meningococcal conjugate vaccine in healthy adolescents. Results have b…
-
CLINICAL_TRIALS trial_result · 2013-11-05Clinical Trial Update: Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age [Phase 3]
Phase 3 trial comparing meningococcal ACWY conjugate vaccine to polysaccharide vaccine in children aged 2-10 assessing safety and immunogeni…
-
CLINICAL_TRIALS trial_result · 2013-10-18Clinical Trial Update: Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine [Phase 3]
Phase 3 trial update reporting on the persistence of antibody responses in children previously vaccinated with Novartis MenACWY Conjugate Va…
-
FDA label_change · 2013-06-27FDA Approved: RIFAMPIN — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for Rifampin filed by Chartwell RX, LLC, leading to changes in the product labeling.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-05-09Clinical Trial Update: Understanding the Persistence of Immunity After MenC Vaccines
This trial update reports on the persistence of immunity after meningococcal group C vaccines in healthy individuals. The study, conducted b…
-
CLINICAL_TRIALS trial_result · 2013-03-15Clinical Trial Update: Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers [Phase 3]
Phase 3 trial evaluating the safety and immune response of the MenACWY-CRM meningococcal conjugate vaccine in healthy toddlers; results comp…
-
CLINICAL_TRIALS withdrawal · 2013-02-20Clinical Trial Update: A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger
Status update indicating that the case-control trial evaluating the efficacy of MenAfriVac in Mali and Niger has been withdrawn. The study a…
-
CLINICAL_TRIALS trial_result · 2012-10-16Clinical Trial Update: A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea [Phase 3]
This Phase 3 trial evaluated the immunogenicity and safety of the MenACWY meningococcal conjugate vaccine in adolescents and adults in Korea…
-
CLINICAL_TRIALS trial_result · 2012-09-19Clinical Trial Update: Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months [Phase 2]
Phase 2 trial evaluating the immune response to a meningococcal ACWY conjugate vaccine in children aged 40 and 60 months; results were poste…
-
CLINICAL_TRIALS trial_result · 2012-08-06Clinical Trial Update: Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine [Phase 3]
Phase 3 trial comparing Hib-MenCY-TT vaccine to licensed Hib conjugate vaccine assessing safety and immunogenicity; completed with results p…
-
CLINICAL_TRIALS trial_result · 2012-07-23Clinical Trial Update: Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine [Phase 2]
Phase 2 dose-ranging study evaluating Hib-MenCY-TT vaccine; completed with results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-07-20Clinical Trial Update: Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines [Phase 2]
Phase 2 clinical trial update evaluating Hib-MenCY-TT vaccine compared with licensed Hib and meningococcal serogroup C vaccines; study compl…
-
CLINICAL_TRIALS trial_result · 2012-07-20Clinical Trial Update: Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. [Phase 3]
Phase 3 trial comparing Hib-MenCY-TT vaccine to a licensed Haemophilus influenzae type b conjugate vaccine in children aged 12 to 15 months,…
-
CLINICAL_TRIALS trial_result · 2012-07-20Clinical Trial Update: Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB [Phase 3]
Phase 3 trial assessing long-term antibody persistence at 1, 3, and 5 years after a fourth Hib-MenCY-TT dose, compared with ActHIB.
-
CLINICAL_TRIALS trial_result · 2012-07-20Clinical Trial Update: Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age [Phase 3]
A Phase 3 trial comparing Hib-MenCY-TT with a licensed Haemophilus influenzae type b conjugate vaccine in infants shows safety data; the stu…
-
CLINICAL_TRIALS trial_result · 2012-06-19Clinical Trial Update: Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination [Phase 2]
Phase 2 clinical trial assessing antibody persistence and response to re-vaccination with Menactra or Menomune three years after initial men…
-
CLINICAL_TRIALS trial_result · 2012-05-22Clinical Trial Update: Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612 [Phase 3]
Phase 3 study by GlaxoSmithKline Biologicals evaluating non-inferiority and immunogenicity of Meningococcal Vaccine 134612 has completed wit…
-
CLINICAL_TRIALS trial_result · 2012-03-27Clinical Trial Update: Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac
A completed clinical trial update assessing immunogenicity after two doses of the meningococcal outer membrane vesicle vaccine MenBVac.
-
CLINICAL_TRIALS trial_result · 2012-03-23Clinical Trial Update: Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®
A clinical trial evaluated the immune response to Neisseria meningitidis serogroup B vaccine MenBVac in 16 participants; the study has compl…
-
CLINICAL_TRIALS trial_result · 2012-02-08Clinical Trial Update: Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children [Phase 3]
Phase 3 trial evaluating immunogenicity, safety, tolerability, and memory priming potential of a Meningococcal C conjugate vaccine in health…
-
CLINICAL_TRIALS trial_result · 2011-10-24Clinical Trial Update: Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents [Phase 2]
A Phase 2 trial evaluating the immunogenicity and safety of several rMenB Plus MenACWY vaccine formulations in adolescents has completed.
-
CLINICAL_TRIALS trial_result · 2011-09-13Clinical Trial Update: A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY [Phase 2]
A Phase 2 trial assessing how long the immune response lasts and the immune response after a booster dose of the MenACWY meningococcal vacci…
-
CLINICAL_TRIALS trial_result · 2011-08-23Clinical Trial Update: Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults [Phase 1, Phase 2]
Phase 1/2 safety and blood collection study of a meningococcal B vaccine (RLP2086) in adults has completed.
-
CLINICAL_TRIALS trial_result · 2011-07-08Clinical Trial Update: Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults [Phase 2]
Phase 2 study evaluating safety, tolerability, and immunogenicity of three doses of the Novartis Meningococcal B Vaccine in healthy at-risk …